Constellation Pharmaceuticals is a biopharmaceutical company working to address unmet medical needs in cancer patients by selectively modulating gene expression. The company's focus is on epigenetic and chromatin modifications in cancer cells and tumor microenvironments. Constellation is currently developing CPI-0610, a BET inhibitor for myelofibrosis, and CPI-0209, an EZH2 inhibitor for solid tumors. The company is also exploring other novel targets that impact gene expression to build a diverse pipeline of small-molecule product candidates.